Log in

Newsletter of the Human Proteome Organization

Current and past HUPOSTs are posted here for your review. Stories, highlights, news, and announcements are gladly accepted for inclusion in the HUPOST. Please submit your information to the HUPO Office at office@hupo.org.


  • 30 May 2019 2:59 PM | Anonymous member (Administrator)

    Edouard Nice, Monash University, Australia and Mark Baker, Macquarie University, Australia

    As part of the interaction between HUPO and the Royal College of Pathologists of Australasia (RCPA), especially in Education and Training, there was strong HUPO participation in the recent “Pathology Update: The Power of Personalized Pathology” conference held at the Melbourne Convention Centre from 22nd to 24th February 2019. This meeting was attended by over 1350 delegates, including medics, pathologists, scientists, trainees and healthcare workers, with strong industry support (over 30 companies at the trade exhibition).

    Prof Dan Chan opened the meeting with the David Rothfield Memorial Oration with a talk entitled “The success of Precision Pathology: Multi-Omics Building Blocks”. He explained how advances in cancer pathobiology that have helped elucidate the intricate cell signalling mechanisms that trigger oncogenesis are due to the combined effect of genomic, transcriptomic, epigenetic and proteomic changes. He gave examples of how significant advances in molecular technologies, such as the multiplex-polymerase chain reaction (PCR), next generation sequencing (NGS) and mass spectrometry (MS), coupled with computational medicine, have identified new biomarkers for improving disease classification and diagnosis, including the recently reported CancerSEEK test, which uses a combination of assays for genetic alterations and protein biomarkers, and has the capacity not only to identify the presence of relatively early cancers but also to identify their localisation. Prof Chan also made other presentations at the meeting on “Tumour Markers in Practice” and Understanding immunoassay: a practical guide” as part of the Chemical Pathology agenda. In a complimentary plenary talk on the Saturday morning, Prof Eva Raik discussed ‘Precision Cancer Medicine – cup half full or cup half empty’ discussing both the advantages and hurdles that currently exist.

    On Sunday 24th a whole session was devoted to “Clinical Proteomics: Development of a Pathology Partnership”. This session was organised by Profs Ed Nice, Mark Baker and Dan Chan for HUPO and Profs Peter Stewart and Andrea Horvath representing the RCPA. The session was chaired by Dan, and comprised four talks. Ed Nice led off with a talk entitled “Clinical proteomic biomarker discovery and translation for pathology”. This started with an introduction to HUPO and the new Pathology Pillar, and the requirement for a strong interaction with clinicians and pathologists as we enter the transitional phase of proteomics. He then outlined the role of faecal proteomics in GI tract pathology.

    This was followed by a talk from Prof Horvath on “Evidence-based evaluation of proteomic biomarkers: from unmet medical needs to clinical application” in which she described proteomics as the Knight in Shining Armour. Using a hypothetical on acceptance of biomarkers that have better performance than current tests for coronary atherosclerosis, she introduced several recent proteomics examples from the literature. She stressed the importance of unmet clinical need and validation in successful translation. Dr Steven Ramsay gave a presentation on “Challenges of developing protein biomarker assays for clinical use - method validation and quality issues” further illustrating the importance of this issue, using IGF1 as an example.

    To close the session, Prof Peter Stewart, former president of the RCPA, acting as devils advocate, with a concept like the “glass half full or half empty concept introduced earlier in the meeting, discussed the “Barriers to adoption of Proteomics in clinical diagnosis”. He highlighted areas such as the complexity of the technology, measurement errors, throughput, skill base in technology and informatics and the need to up-skill pathologists (the goal of the HUPO-RACP collaboration), clinical utility and the cost and reimbursement rates.

    All the slides that were presented in this session are currently available on line at https://www.rcpa.edu.au/Events/Pathology-Update/Post-Conference. Further joint HUPO/RACP sessions to further advance education and training are being planned for 2020.

    Clinical Proteomics: Development of a Pathology Partnership.
    From left to right: Prof Peter Stewart, Prof Dan Chan
    Prof Rita Horvath, Dr Steven Ramsey, Prof Ed Nice

    Pathology Update: The Power of Personalized Pathology
    From left to right: Prof Ed Nice, Prof Peter Stewart, Prof Dan Chan

  • 01 May 2019 10:24 AM | Anonymous member (Administrator)

    Marta del Campo Mila, VU University, Medical Centre, Amsterdam, 
    Charlotte Teunissen, VU University, Medical Centre, Amsterdam, 

    The HUPO Brain Proteome Project (HBPP) Steering Committee invites you to register for the 29th HUPO Brain Proteome Project Workshop, which will be held on 27th and 28th of May 2019 in Amsterdam. 

    HBPP Spring Workshops cover a wide range of topics relevant to neuroproteomics research. The program is highly dynamic and interactive, and all participants are given the opportunity to give an oral presentation on their research or updates of novel techniques and analytical approaches used in their labs. Workshops have included, for example, sessions on myelin proteomics, autoimmunity, and bioinformatics.

    HBPP is committed to a strong clinical and translational focus. Hence, sessions in last meetings were dedicated to proteomics of psychiatric disorders, movement disorders, spinal cord injury & trauma, dementia, and cancers of the CNS. On top of that, there will be a very nice evening program that will allow all the delegates to have relax interactions with a unique local atmosphere.

    The HBPP Steering Committee encourages every researcher interested in brain proteomics, including junior scientists to join this event. For more information about the workshop please visit https://www.hbpp2019.com/.

    Don’t hesitate to extent and share this information between all your colleagues within the field.

    We are looking forward to see your latest results at this inspiring meeting!

    On behalf of the HBPP steering committee, thank you. 

  • 01 May 2019 9:50 AM | Anonymous member (Administrator)

    Kun-Hsing Yu (Harvard Medical School) and Maggie Lam (University of Colorado)

    Among the missions of the HUPO Biology/Disease-driven Human Proteome Project (B/D-HPP) initiatives is to identify popular proteins in the human proteome associated with diseases and biological systems. Recently, there has been a number of software tools emerging that allow researchers to prioritize crucial proteins in various organ-systems and diseases from the biomedical literature. Information obtained using such tools which can be used to facilitate the development and promote the application of proteomics assays, such as multiple reaction monitoring to target disease-specific proteins. Our B/D-HPP groups have capitalized on these resources and made significant strides in assembling and sharing prioritized protein lists relevant to their biological systems and diseases of interest. Below we provide a brief overview of some of these software tools that enable the prioritization of popular proteins. These tools provide users ways to search and prioritize proteins related to their research interest and will facilitate targeted proteomics studies. Future algorithm and software development can further enable the prioritization of various proteoforms, such as phosphoproteome, glycoproteome, and alternative splicing isoforms, which will advance our understanding of the human proteome in health and disease states.

    PubPular (Lau et al. J Proteome Res. 2018)
    PubPular is an R/Shiny web interface for querying and visualizing popular proteins for custom search terms using Gene2PubMed/PubTator data sources and semantic similarity metrics. Recent updates of PubPular also support the query of pre-compiled protein lists from Disease Ontology and Human Phenotype Ontology disease terms as well as reverse protein-to-topic searches. PubPular can be accessed via http://pubpular.net.

    PURPOSE and metaPURPOSE (Yu et al. J Proteome Res. 2018)
    The Protein Universal Reference Publication-Originated Search Engine (PURPOSE) tool prioritizes proteins by the strength and specificity of the associations between proteins and the query terms. For each query, the number of PubMed publications are retrieved in real-time, and the results are summarized in the user-friendly web interface. PURPOSE is accessible through http://rebrand.ly/proteinpurpose.

    metaPURPOSE is an extension of PURPOSE and prioritizes metabolites associated with any search terms. This tool addresses the challenges arisen from multiple synonyms associated with common metabolites and uses the PURPOSE algorithm to rank the retrieved metabolites. metaPURPOSE is hosted at http://rebrand.ly/metapurpose.

    GLAD4U (Jourquin et al. BMC Genomics. 2012)
    Gene List Automatically Derived For You (GLAD4U) is a web-based tool that allows users to retrieve a prioritized list of Entrez-Gene IDs. The tool leverages the hypergeometric test to rank the list of biological entities associated with the query. Their user interface enables users to download the query results, conduct functional enrichment analysis using WebGestalt, and view the detailed publication list related to the retrieved genes. The GLAD4U tool is at http://glad4u.zhang-lab.org.

    FACTA+ (Tsuruoka et al. Bioinformatics. 2011)
    Finding Associated Concepts with Text Analysis+ (FACTA+) is a text mining tool developed by the National Centre for Text Mining (NaCTeM), School of Computer Science, The University of Manchester, UK. The tool aims to assist users to identify associations among biomedical concepts, including genes, proteins, diseases, symptoms, drugs, and chemical compounds. For each query term, the associated biomedical concepts are retrieved and ranked. Users can view the snippets from the literature that describe the association. FACTA+ also allows users to find indirectly associated concepts by ranking the second-order associations between the query term and the target concepts. For access, go to http://www.nactem.ac.uk/facta/.

  • 01 May 2019 9:37 AM | Anonymous member (Administrator)

    Péter Horvatovich, University of Groningen, Netherlands

    The dark proteome is defined accordingly to C-HPP as “a colloquial term that includes missing proteins (PE2 – PE4), uncertain/dubious predicted proteins (PE5), uPE1 proteins, smORF (small proteins), and any proteins translated by long non-coding RNAs or uncharacterized transcripts including those arising from non-coding regions of DNA and/or novel alternative splicing.” The central theme of the 21st C-HPP symposium is “Illuminating the Dark proteome” and will take place in May 12 – 14, 2019 in Saint Malo (France) at the Hotel France & Chateaubriand, which is located inside the fortified city.

    The complete scientific program and abstracts are now available online home page of the event and at C-HPP Wiki. The program – amongst others – includes discussion of the 3.0 version of Human Proteome Project Data Interpretation Guidelines, updates on neXtProt, PeptideAtlas, as well as progress on neXt-CP50 and neXt-MP50 challenges. Keynote lectures will be provided by:

    • Nuno Bandeira (University of California, San Diego) on “ProteinExplorer: integration of community-scale big data for assessment of protein existence”.
    • Anne-Claude Gingras (Lunenfeld-Tanenbaum Research Institute,Toronto, Canada) on “Dark proteome: shedding light on localization and interaction of uncharacterized proteins”.
    • Yves Vandenbrouck (CEA Grenoble, France) on “Exploring the dark side of the Human proteome using the ProteoRE platform”.
    • Mirjam Czjzek (Roscoff Marine Station, Roscoff, France) on “How structural biology contributes to uncover biochemical functions of putative proteins”.
    • Fernando Corrales (Centro Nacional de Biotecnología , Madrid, Spain) on “Bridging C and B/D HPP to define the biological context of human proteins PTM” (Abstract 12).
    • Marie-Christine Birling (IMPC, Strasbourg, France) on “The virtuous cycle of human genetics and mouse (and rat) models”.

    In addition 23 talks were selected from the abstracts.

    The organisers Charles Pineau, Chris Overall, Young-Ki Paik, Lydie Lane are looking forward to meeting with all C-HPP members and all interested participants, especially B/D-HPP members.

  • 26 Mar 2019 12:25 PM | Anonymous member (Administrator)

    Dr Ying Jiang, Beijing Institute of Lifeomics, Beijing, China 

    Hepatocellular carcinoma (HCC) is the third leading cause of deaths from cancer worldwide. Infection with the hepatitis B virus is one of the leading risk factors for developing HCC, particularly in East Asia. Although surgical treatment may be effective in the early stages, the five-year overall rate of survival after developing this cancer is only 50–70%. Proteomic and phospho-proteomic profiling of 110 paired tumour and non-tumour tissues of HCC stratifies HBV-related early-stage disease into 3 prognostic subtypes. The disrupted cholesterol homeostasis is characterized in the subtype associated with the lowest overall rate of survival and the greatest risk of a poor prognosis after first-line surgery. Moreover, targeting SOAT1 (either knock-down or inhibitor treatment) suggests opportunities for personalized therapies. In conclusion, CNHPP study identifies the proteomic landscape in early HCC, and the patterns of protein signatures and pathways that are altered in proteomic subtypes of HCC. The drug-targetable proteins that identified by proteomic alterations may provide a powerful tool for identifying patients with HCC subtypes associated with a poor prognosis, and who might benefit from further targeted treatment, moving us towards the era of proteomics-driven precision medicine.

    National Center for Protein Sciences (Beijing) 

  • 26 Mar 2019 10:36 AM | Anonymous member (Administrator)

    Péter Horvatovich, University of Groningen, Netherlands

    The dark proteome is defined accordingly to the HPP as “a colloquial term that includes missing proteins (PE2 – PE4), uncertain/dubious predicted proteins (PE5), uPE1 proteins, smORF (small proteins), and any proteins translated by long non-coding RNAs or uncharacterized transcripts including those arising from non-coding regions of DNA and/or novel alternative splicing.” The central theme of the 21st C-HPP symposium is “Illuminating the Dark proteome” and will take place in May 12-14, 2019 in Saint Malo (France) at the Hotel France & Chateaubriand, which is located inside the fortified city.

    The program is currently available online on the home page of the event and on the C-HPP Wiki. The program – among others – includes discussion of the version 3.0 of Human Proteome Project Data Interpretation Guidelines, updates on neXtProt, PeptideAtlas, progress on neXt-CP50 and neXt-MP50 challenges. Key-note lectures will be provided by:

    • Nuno Bandeira (University of California, San Diego) on “ProteinExplorer: integration of community-scale big data for assessment of protein existence
    • Anne-Claude Gingras (Lunenfeld-Tanenbaum Research Institute,Toronto, Canada) on “Dark proteome: shedding light on localization and interaction of uncharacterized proteins”
    • Yves Vandenbrouck (CEA Grenoble, France) on “Exploring the dark side of the Human proteome using the ProteoRE platform”
    • Marie-Christine Birling (IMPC, Strasbourg, France) on “The virtuous cycle of human genetics and mouse (and rat) models”

    Besides C-HPP, B/D HPP PIC and young investigators will contribute to the program. Places are limited, but registration for the workshop is still possible online using a registration form. The hotel block has been completely filled, but we are hoping to free some more rooms from the hotel stock available till first week of April. However, this is uncertain and in that case another hotel will have to be sought by the registrants.

    The organisers Charles Pineau, Chris Overall, Young-Ki Paik, Lydie Lane are looking forward to receive all C-HPP members and all interested participants from B/D-HPP and HUPO membership.

  • 26 Mar 2019 10:04 AM | Anonymous member (Administrator)

    Jennifer Van Eyk, Burcu Ayoglu, Ferdinando Cerciello, Justyna Fert-Bober, Ruth Hüttenhain, Mathieu Lavallée-Adam, Adriana Franco Paes Leme, Giuseppe Palmisano, Ilaria Piazza, Fábio César Sousa Nogueira)

    The ECR was launched as a new HUPO initiative at HUPO 2015 World Congress in Vancouver. The intent of the ECR is to be an open and easily reachable platform dedicated to the new generation of proteomics scientists of the HUPO community.

    The ECR aims are to (1) promote connection between generations of proteomics scientists along the visions and the ideals of HUPO; (2) promote the scientific work of the new generation of proteomics scientists and to provide training and support for their early career development; (3) promote interaction and international collaboration among early career investigators in proteomics.

    To achieve these aims, we explored common facilitators and challenges faced by early career researchers in proteomics during annual Mentoring Day at HUPO world congresses. The program of Mentoring Day, every year is different and has several ingredients to enhance an ECR individual’s success. Having supportive collegial relationships, institutional support, job security, and funding are critical facilitators for early career investigators. Key challenges include difficulty with time management and prioritizing, limited resources, and contacts. The talks, conversations and friendly atmosphere during Mentoring day, can potentially help transfer knowledge and expertise since it represents a variety of professional backgrounds and experience from more mature generation. This is also an exceptional opportunity to approach and interact with current and future world-renowned leaders in proteomics! For example, the focus of the mentoring day at HUPO2018 in Orlando was on “communication” and the program included various topics such as “what qualities are necessary for successful communication?”, “ten simple rules for choosing between industry and academia”, “communicating with funding agencies”, etc. Our mentors in Orlando were Beth Anderson (Arkitek Scientific), Nicolai Bache (Evosep), Sixue Chen (University of Florida, USA), Benjamin Garcia (University of Pennsylvania School of Medicine, USA), Arianna Jones (Sciex), Kathryn Lilley (Cambridge Centre for Proteomics. University of Cambridge. UK), Stephen R. Pennington (UCD Conway Institute, Dublin), Robert Rivers (NIH, USA), Jennifer Van Eyk (Cedars Sinai Medical Center).

    ECR also promotes the scientific work of the new generation by organizing manuscript competition. For the manuscript competition, early career researchers are invited to submit their scientific work in form of a manuscript, which has either been published or accepted for publication within the previous year. Three finalists are then invited to present their research at the HUPO world congress to select the proteomic highlight of the year. For our most recent manuscript competition at HUPO2018 in Orlando we had three winners, Dr. Ruth Hüttenhain (University of California, San Francisco, USA), Dr. Mathieu Lavallée-Adam (University of Ottawa, Canada) and Dr. Ilaria Piazza (Swiss Federal Institute of Technology-ETH Zurich, Switzerland)! (pictures of the winners are reported below)

    In addition to the already established activities, the ECR proudly contributed to the success of the HUPO PhD poster competition at HUPO2018 in Orlando. While the poster competition is an already established and successful tradition of HUPO, ECR started to be involved in organizing the competition as a way to highlight the work of very early career scientists! Eight finalists of the competition were selected to present their work in a three-minute power point presentation and Desmond Li (University of Sydney), Aaron Robinson (Cedars Sinai Medical Center) and Amber Weiner (University of Pennsylvania) were the winners of last year’s final! (pictures of the finalists are reported below, but CAVE: they have already been presented in a previous HUPOST)

    HUPO2018 in Orlando was not only important for the ECR for expanding their activities but also for kicking off a bigger working committee. In 2015 ECR was successfully established by Dr. Burcu Ayoglu (KTH Royal Institute of Technology), Dr. Ferdinando Cerciello (University Hospital of Bern) and Dr. Justyna Fert-Bober (Cedars Sinai Medical Center) under the mentoring of Prof. Jennifer Van Eyk (Cedars Sinai Medical Center). To expand ECR activities they are now joined by the three finalists of the 2018 ECR manuscript competition (Dr. Ruth Hüttenhain, Dr. Mathieu Lavallée-Adam and Dr. Ilaria Piazza) as well as Dr. Giuseppe Palmisano (University of San Paolo, Brazil), Dr. Fábio César Sousa Nogueira (Federal University of Rio de Janeiro, Brazil) and Dr. Adriana Franco Paes Leme (Brazilian Biosciences National Laboratory, Brazil).

    And our new members are already at hard work! Indeed, we are working on identifying new and additional opportunities to support and promote the scientific work of early career scientists, ideally in form of collaborative grants between young scientists. We are also working on defining a curriculum of “must to know” for early career scientists in proteomics. We hope that we will be able to join forces with already experienced education initiatives within HUPO and other groups of young researchers in proteomics in order to be able to establish together a series of master classes in proteomics dedicated to the early career researchers. In addition, we are reaching out to regional early career proteomics communities across the globe to connect and join forces with the intention to identify needs of early career researchers in proteomics, to further expand ECR activities and to support building up new regional communities for early career researchers!

    Finally, a motivation for all early career researchers in proteomics to get ready for HUPO2019 in Adelaide:

    • Submit your manuscript for the ECR Manuscript Competition and your abstract for the ECR PhD Poster Competition
    • Sign up for participating in the ECR Mentoring Day
    • Contact us if you are interested in contributing to the work of ECR

    And finally, a warm thank you for reading about our progresses!

    The ECR working committee

    The winners of the ECR manuscript competition at HUPO2018 in Orlando (from left to right): Dr. Ruth Hüttenhain (University of California, San Franciso, USA), Dr. Mathieu Lavallée-Adam (University of Ottawa, Canada), Dr. Ilaria Piazza (Swiss Federal Institute of Technology-ETH Zürich, Switzerland).

    The finalists of the PhD poster competition: Shubham Gupta (Canada), Andreas Hober (Sweden), Desmond Li (Australia), Benjamin Pullman (USA), Aaron Robinson (USA), Tim Van Den Bossche (Belgium), Amber Weiner (USA), Juanjuan Xie (China).

  • 01 Mar 2019 12:10 PM | Anonymous member (Administrator)

    Péter Horvatovich, University of Groningen, Netherlands

    The Journal of Proteome Research will publish its seventh annual Special Issue dedicated to highlight progress on the HUPO Human Proteome Project (HPP). The Special Issue considers papers encompassing both the Chromosome-Centric Human Proteome Project (C-HPP) and the Biology and Disease Human Proteome Project (B/D-HPP). In addition, we will now consider short definitive reports, submitted in the Letters format, on the discovery of a Missing Protein(s). To be considered, the missing protein(s) must meet the Guidelines v 2.1 or later when available, and be put in the context of both the HPP and biological setting in which they were discovered. We anticipate this format will encourage many teams, particularly of the B/D-HPP, to highlight such protein discoveries in a disease and biological context.

    Guest Editors

    Young‐Ki Paik, Yonsei University
    Eric Deutsch, Institute for Systems Biology
    Fernando Corrales, Centro Nacional de Biotecnología (CSIC)
    Lydie Lane, Swiss Institute of Bioinformatics
    Gilbert S. Omenn, University of Michigan

    Associate Editor

    Christopher M.Overall, The University of British Columbia

    Thematic Priorities:

    • Completing the high-resolution draft of the human proteome with new strategies and results leading to confident identifications of neXtProt missing proteins (PE2 – 4) according to the C-HPP Guidelines v 2.1 or recent updates
    • Progress on the protein list of individual chromosomes and groups of chromosomes, annotating known proteins and their isoforms/proteoforms and/or credibly identifying missing proteins (PE2 – 4)
    • Annotating proteins and their isoforms/proteoforms and/or identifying missing proteins found in rare or under explored cells and tissues, and protein lists of human cell types as a step in creating a human cell proteome atlas
    • Produce and utilize “popular proteins” lists in B/D-HPP and contribute to the identification of missing proteins
    • Proteomic studies of proteoforms produced by proteolytic processing, PTMs, alternative splicing (ASV),
    • coding non‐synonymous single nucleotide polymorphisms (cSNPs), or chromosome abnormalities
    • Use of targeted proteomics, especially SRM and MS‐SWATH, to extend chromosome‐based protein findings
    • Disease studies utilizing chromosome information, characterizing amplicons, cis‐regulated pathways or networks
    • New bioinformatic tools and approaches for annotating the human proteome
    • Biological mechanistic analyses inspired from proteomics data in diseases or biological processes
    • Biomarker discoveries based on the identification of novel ASVs, PTMs or cSNPs in proteomic studies

    Submission Procedure

    Manuscripts must be submitted by 31st May, 2019 to be considered for this Special Issue. Manuscripts must be submitted electronically through the ACS Paragon Plus Environment online submission system. Specify in the authors’ cover letter that the manuscript is intended for the HPP Special Issue.

    Review and Publication Process

    Initial editorial review will determine whether manuscripts are appropriate for the HPP Special Issue and fulfill the HPP checklist (http://www.thehpp.org/guidelines/HPPDataGuidelines_2.1.0.pdf) to be considered for publication. The completed checklist must be included with the cover letter. The full MS data submission to ProteomeXchange must also be completed prior to initial submission, and the PXD number provided in the abstract. Nonconforming papers will be returned unreviewed. All relevant papers will go through full peer review. As papers are accepted they will go online and be available in time for HUPO-2019. Due to the publication schedule, only papers that are accepted by September 31, 2019 will be published in the December 2019 HPP Special Issue. Papers requiring more time for revision or falling outside of the scope of the Special Issue will be published in regular issues of the Journal

    HPP Data Guidelines

    Papers must conform to both the Journal of Proteome Research mass spectrometry guidelines and the HPP guidelines v 2.1 (see Deutsch et al. http://pubs.acs.org/doi/abs/10.1021/acs.jproteome.6b00392) in order to be sent to review and for acceptance. Please check for any changes to the HPP guidelines available online at http://www.thehpp.org/guidelines/ before submission. All papers must analyze their data using the Human PeptideAtlas release 2019-01 and neXtProt release 2019-02. Papers not doing so will be returned without review.

    21st C-HPP symposium “Illuminating the Dark proteome” - Saint Malo, France, May 12-14, 2019

    The central theme of the 21st C-HPP symposium is to discuss approaches and topics on “Illuminating the Dark proteome”, a colloquial term that includes missing proteins (PE2 – PE4), uncertain/dubious predicted proteins (PE5), uPE1 proteins, smORF (small proteins), and any proteins translated by long non-coding RNAs or uncharacterized transcripts including those arising from non-coding regions of DNA and/or novel alternative splicing. The symposium will also welcome speakers from the B/D-HPP to discuss the functionalization of the dark proteome.

    Saint-Malo, historical home of great discoverers and corsairs, is a fortified city located on the north coast of Brittany. The symposium will take at the Hotel France & Chateaubriand, which is located inside the “stone vessel” (the nickname of the fortified city). Registration for the symposium can be done online using a registration form that must be sent directly to the hotel. We are pleased to announce that the deadline of abstract submission has been extended up to March 11. Please visit https://c-hpp.univ-rennes1.fr/ for more details.

    For sure, the wonderful location and relaxing atmosphere of Saint-Malo will allow participants of the symposium to exchange fruitfully and informally. Yet, spring has arrived in the Corsair City…

  • 28 Feb 2019 4:44 PM | Anonymous member (Administrator)

    A message from Cabezon Group and Clarivate Analytics

    The National Cancer Institute’s (NCI) Office of Cancer Clinical Proteomics Research (OCCPR) has contracted with Cabezon Group and Clarivate Analytics to conduct a third-party, external evaluation which includes a research survey of the external perception of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) program. The survey is designed to be relatively short and should only take approximately 10 to 15 minutes to complete. To complete the survey, please click on https://www.surveymonkey.com/r/CPTAC_HUPO.

    Your strictly voluntary and confidential participation in the survey is vital to our evaluation efforts. The goals of the survey are to examine the impact of CPTAC on the broader field of proteogenomics; how the proteogenomic research community perceives the CPTAC program; and to assess the impact that specific CPTAC program components and actions have had on the research community. Your feedback provides a collaborative, shared understanding of program perceptions which enables improvements intended to benefit future CPTAC activities and impact.

    The research results from the evaluation and survey will be disseminated publicly. A summary of the survey results will be placed on the Office of Cancer Clinical Proteomics public website (proteomics.cancer.gov). In addition, the survey results will be presented at the 2020 annual CPTAC meeting.

    You may forward the survey invitation/link to colleagues, but we ask that there is no addition or modification to the invitation message. If you have already completed this survey from another list serve we ask that you do not complete it again.

    Thank you for your time and participation.

  • 28 Feb 2019 9:27 AM | Anonymous member (Administrator)

    Vera Ignjatovic,University of Melbourne, Australia

    Glycoproteomics holds immense potential to advance understanding of the molecular and cellular processes underpinning human (patho)physiology, but remains an analytically challenging discipline (Thaysen-Andersen M et al., Mol Cell Proteomics. 15(6):1773. 2016). Accurate automated intact glycopeptide identification from high resolution tandem mass spectrometry data, a prerequisite for the further advancement of glycoproteomics, is still in its infancy despite many exciting glycoinformatics developments (Hu et al., Mass Spectrom Rev. 36(4):475. 2017).

    Formed in September 2016, the first community study of the B/D-HPP Human Glycoproteomics Initiative (HGI) sets out to provide a detailed comparison of the bioinformatics solutions currently in use for the site-specific determination of protein N- and O-linked glycosylation. For this purpose, two high resolution CID-, HCD- and EThcD-based LC-MS/MS glycopeptide datasets were acquired from a tryptic digest of serum glycoproteins and these two common data files were distributed to all study participants. The participating teams were asked to return lists of confidently identified N- and O-glycopeptides from the two LC-MS/MS data files using preformed reporting templates and, further, to provide information of their used method of identification. Significant efforts by the HGI study committee were invested to ensure uniformity and compliance of all teams with the study guidelines.

    An update of the study progress was presented by Dr Thaysen-Andersen at the B/D-HPP Investigator Meeting during the 17th World Congress HUPO, Orlando, FL. The study has been very well received by the community with 22 glycoproteomics laboratories encompassing 9 software developers and 13 user teams located across all major continents completing the identification task by the end of the reporting deadline (October 2018). Recent analysis of the glycopeptide data reports by the HGI study committee encouragingly shows the existing of diverse informatics tools and approaches with a great potential for (semi-)automated glycopeptide identification from complex LC-MS/MS datasets, but, at the same time, highlighted a significant variance of glycopeptide/protein identifications within and between the user and developer teams. Discordance was also observed between participants using the same software. The underlying reasons for this spread and further data comparisons to delineate the more exact overlap and differences between the glycopeptides reported by the 22 teams are currently being investigated.

    We aim to publish the 1st HGI study results in 2019 and will present the final study outcomes at the 2nd Australasian Glycoscience Symposium (2nd AGS) to be held on the 14th September in Adelaide, Australia (more information to follow) immediately prior to the 18th World Congress HUPO, Adelaide, Australia where the prospects and scope of a potential 2nd HGI study also will be discussed.

The Human Proteome Organization is a 501(c)(3) tax exempt non-profit organization registered in the state of New Mexico.  |  © 2020 HUPO

Powered by Wild Apricot Membership Software